The diagnostic and prognostic role of cytokines in colon cancer

References

• Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–2114.
   PubMed Web of Science ®Google Scholar
• Laukoetter MG, Mennigen R, Hannig CM, et al. intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg. 2010;15(4):576–583.
   Web of Science ®Google Scholar
• Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29(7):2727–2737.
   PubMed Web of Science ®Google Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell. 2004;118(6):671–674.
   PubMed Web of Science ®Google Scholar
• Il’yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413–2418.
   PubMed Web of Science ®Google Scholar
• Link KH, Sagban TA, Morschel M, et al. Colon cancer: survival after curative surgery. Langenbecks Arch Surg. 2005;390(2):83–93.
   Web of Science ®Google Scholar
• Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1–8.
   PubMed Web of Science ®Google Scholar
• Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol. 2009;25(5):422–427.
   Web of Science ®Google Scholar
• Van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol. 2010;24(4):479–492.
   Web of Science ®Google Scholar
• Lund EK, Belshaw NJ, Elliott GO, Johnson IT. Recent advances in understanding the role of diet and obesity in the development of colorectal cancer. Proc Nutr Soc. 2011:1–11.
   Web of Science ®Google Scholar
• Kulaylat MN, Dayton MT. Ulcerative colitis and cancer. J Surg Oncol. 2010;101(8):706–712.
   Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Osawa E, Nakajima A, Fujisawa T, et al. Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer. 2006;118(9):2232–2236.
   PubMed Web of Science ®Google Scholar
• Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol. 2009;31(2):249–256.
   Web of Science ®Google Scholar
• McBee ME, Zeng Y, Parry N, Nagler CR, Tannenbaum SR, Schauer DB. Multivariate modeling identifies neutrophil- and Th17-related factors as differential serum biomarkers of chronic murine colitis. PLoS One. 2010;5(10):e13277.
   Web of Science ®Google Scholar
• Wang CS, Sun CF. C-reactive protein and malignancy: clinico- pathological association and therapeutic implication. Chang Gung Med J. 2009;32(5):471–482.
   Google Scholar
• Yan Y, Kolachala V, Dalmasso G, et al. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE. 2009;4(6):e6073.
   PubMed Web of Science ®Google Scholar
• Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963):296–300.
   PubMed Web of Science ®Google Scholar
• Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer. 2000;83(11):1443–1447.
   Web of Science ®Google Scholar
• Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflam- masome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045–1056.
   PubMed Web of Science ®Google Scholar
• Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32(3):379–391.
   PubMed Web of Science ®Google Scholar
• Xiao H, Yin W, Khan MA, et al. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology. 2010;139(2):574–585.
   Web of Science ®Google Scholar
• Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32(3):367–378.
   PubMed Web of Science ®Google Scholar
• Salcedo R, Worschech A, Cardone M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med. 2010;207(8):1625–1636.
   PubMed Web of Science ®Google Scholar
• Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118(2):560–570.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis- associated cancer. Cancer Cell. 2009;15(2):103–113.
   PubMed Web of Science ®Google Scholar
• Onizawa M, Nagaishi T, Kanai T, et al. Signaling pathway via TNF- alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G850–G859.
   Web of Science ®Google Scholar
• Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 2007;13(1):26–28.
   PubMed Web of Science ®Google Scholar
• Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98(4):1010–1020.
   PubMed Web of Science ®Google Scholar
• Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle. 2005;4(2):217–220.
   Web of Science ®Google Scholar
• Feng T, Wang L, Schoeb TR, Elson CO, Cong Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med. 2010;207(6):1321–1332.
   Web of Science ®Google Scholar
• Koller FL, Hwang DG, Dozier EA, Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis. 2010;31(6):1010–1017.
   Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186–192.
   PubMed Web of Science ®Google Scholar
• Blatner NR, Bonertz A, Beckhove P, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA. 2010;107(14):6430–6435.
   PubMed Web of Science ®Google Scholar
• Xue H, Lu B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res. 2010;9(1):545–555.
   PubMed Web of Science ®Google Scholar
• Kim K, Visintin I, Alvero AB, Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med. 2009;29(1):47–55.
   PubMed Web of Science ®Google Scholar
• Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RW. Applying Random Forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res. 2011;10(3):1361–1373.
   Web of Science ®Google Scholar
• Gourin CG, Zhi W, Adam BL. Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope. 2009;119(7):1291–1302.
   Web of Science ®Google Scholar
• Bunger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137(3):375–389.
   Web of Science ®Google Scholar
• Greco M, Mitri MD, Chiriaco F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalac- tosaminidase activity. Cancer Lett. 2009;283(2):222–229.
   Web of Science ®Google Scholar
• Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14(2):470–477.
   Web of Science ®Google Scholar
• Sarkissian G, Fergelot P, Lamy PJ, et al. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem. 2008;54(3):574–581.
   Web of Science ®Google Scholar
• Yildiz PB, Shyr Y, Rahman JS, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol. 2007;2(10):893–901.
   Web of Science ®Google Scholar
• Belluco C, Petricoin EF, Mammano E, et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol. 2007;14(9):2470–2476.
   PubMed Web of Science ®Google Scholar
• Szkaradkiewicz A, Marciniak R, Chudzicka-Strugala I, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz). 2009;57(4):291–294.
   Web of Science ®Google Scholar
• Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68(1):323–328.
   PubMed Web of Science ®Google Scholar
• Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology. 2011;140(3):799–808.
   PubMed Web of Science ®Google Scholar
• Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I-an independent prognostic factor. Tumour Biol. 2005;26(4):186–194.
   PubMedGoogle Scholar
• Bobe G, Murphy G, Albert PS, et al. Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial. Br J Cancer. 2010;103(9):1453–1461.
   Web of Science ®Google Scholar
• Malicki S, Winiarski M, Matlok M, Kostarczyk W, Guzdek A, Konturek PC. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol. 2009;60(4):141–146.
   Web of Science ®Google Scholar
• Bobe G, Albert PS, Sansbury LB, et al. Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila). 2010;3(6):764–775.
   Web of Science ®Google Scholar
• Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis. 2010;25(2):135–140.
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Yamamoto J, Saltzman B, et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control. 2010;21(7):1131–1138.
   Web of Science ®Google Scholar
• Kwon KA, Kim SH, Oh SY, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 2010;10:203.
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66(4):2483–2487.
   PubMed Web of Science ®Google Scholar
• Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291(5):585–590.
   PubMed Web of Science ®Google Scholar
• Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev. 2006;15(4):690–695.
   Web of Science ®Google Scholar
• Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2010;172(4):407–418.
   PubMed Web of Science ®Google Scholar
• Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med. 2005;142(6):425–432.
   PubMed Web of Science ®Google Scholar
• Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(l):15–26.
   Google Scholar
• Ito Y, Suzuki K, Tamakoshi K, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol 2005;15 Suppl 2:S185–S189.
   Google Scholar
• Ljujic B, Radosavljevic G, Jovanovic I, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010;41(3):182–189.
   Web of Science ®Google Scholar
• Miteva L, Stanilov N, Deliysky T, Mintchev N, Stanilova S. Association of polymorphisms in regulatory regions of interleukin-12p40 gene and cytokine serum level with colorectal cancer. Cancer Invest. 2009;27(9):924–931.
   PubMed Web of Science ®Google Scholar
• Radosavljevic G, Ljujic B, Jovanovic I, et al. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma. 2010;57(2):135–144.
   Web of Science ®Google Scholar
• Lee H, Rhee H, Kang HJ, et al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol. 2008;129(5):772–779.
   PubMed Web of Science ®Google Scholar
• He XX, Chen K, Yang J, et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med. 2009;15(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 2009;125(7):1657–1662.
   PubMed Web of Science ®Google Scholar